Magnus Group solicits your gracious presence at its “5th Edition of International Cancer Conference” (ICC 2022) scheduled as Virtual Event during September 16-17, 2022.
The congress will deliberate on the theme “Combating Cancer with Novel Paradigm in Oncology Research.”
Our forthcoming conference will strike up conversations on the present status of cancer treatment and provide an interactive forum to hear about policies and neoteric changes that are being implemented to help reduce cancer treatment backlogs and, ultimately, improve the health of cancer patients. This two-day conference will provide a timely opportunity to hear from, learn from, and interact with some of the World's finest oncology professionals while networking with like-minded peers.
The agenda of the ICC 2022 is to promote discoveries, evaluate system and strategic issues, and develop and maintain basic systems between analysts, experts, arrangement producers, and healthcare agents through its plenary talks, keynote sessions, oral and poster presentations. We've invited some of the world's most influential speakers including researchers, scientists, oncologists, cancer specialists, pharmacists, clinicians, academicians, young scholars, healthcare professionals, policymakers and industry representatives to provide motivational presentations and workshops.
Join us at ICC 2022 for an interactive environment aimed at improving cancer patient outcomes.
Title : Low angle X - ray fiber diffraction wins gold for Cancer diagnosis
Veronica James, Australian National University, Australia
Title : Electrochemical point-of-care sensor for early diagnosis of Ovarian Cancer
Michael Thompson, University of Toronto, Canada
Title : Digital profiling of protein and microRNA in Rhabdomyosarcoma
Atif A Ahmed, Seattle Children’s Hospital, United States
Title : Muc-mucins of special feature in “nuclear inverse-polarity papillary lesion lacking myoepithelial cells
Shinya Tajima, Shizuoka Medical Center, Japan
Title : The abscission checkpoint: a protector of chromosomal stability
George Zachos, University of Crete, Greece
Title : DOT1L promotes Ovarian Cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis
Romi Gupta, University of Alabama, United States